Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Transcept Gains Long-Delayed Approval Of Intermezzo

This article was originally published in The Pink Sheet Daily

Executive Summary

Indication for insomnia characterized by middle-of-the-night awakening followed by difficulty returning to sleep is a first.

Advertisement

Related Content

Merck’s Suvorexant Driving Claims May Get Green Light After Lunesta Re-Label
Gender-Based Dosing For Insomnia Drugs Dissected In NEJM
Insomnia Drug Development Programs Must Include Driving Studies, FDA Says
Insomnia Drug Development Programs Must Include Driving Studies, FDA Says
Transcept/Purdue’s Intermezzo Gets $29 Million Re-launch
Financings Of The Fortnight: Biotech IPO Trends Continue With Supernus’ Offering – Haircuts, Insider Buys
Bright-Eyed And Bushy Tailed: Purdue Launches Intermezzo
Sleep Agents Update Warnings As FDA Seeks Further Study Of “Complex” AEs

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS073089

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel